Taiwan Showcases Biotech Innovations at BioJapan 2025

The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of Taiwan is leading a delegation of 16 biotech partners to participate in BioJapan 2025, taking place in Yokohama from October 8-10, 2025. This initiative aims to highlight Taiwan’s thriving biotech ecosystem and promote collaborative opportunities with Japanese companies in the fields of artificial intelligence (AI), regenerative medicine, and contract development and manufacturing (CDMO).

BPIPO intends to showcase Taiwan’s strengths in high-growth sectors, emphasizing advancements in regenerative medicine, AI healthcare, and precision health. The Taiwan Pavilion will serve as a platform for industry leaders to connect and explore joint ventures that can drive biotech innovation forward.

Taiwan’s biotech sector has established a significant presence in Japan, with notable collaborations enhancing market penetration. For instance, in 2024, Japan’s CBC became an official distributor for Taiwan’s TBMC, marking a critical step in expanding TBMC’s reach in the Japanese market. Additionally, Leeuwenhoek successfully launched its Flora Le Light Synbiotic in Japan, further solidifying Taiwanese companies’ foothold in the region.

Several strategic partnerships have emerged, reflecting the dynamic collaboration between Taiwanese and Japanese firms. This year, Amaran Biotech formed a partnership with Nippon Fine Chemical to enhance CDMO manufacturing technology for nanoparticle-based drugs. Such collaborations underscore Taiwan’s commitment to innovation in the biotech space.

Taiwanese companies are also making strides with products that cater to a diverse range of industries. For example, AM Biotech‘s high-purity targeted exosomes have gained recognition, being officially registered with the Japan Cosmetic Industry Association. Furthermore, LumiSTAR has been selected for Takeda Pharmaceutical’s COCKPI-T® program, which focuses on advancing drug discovery and development.

The Taiwan delegation will engage in various activities during BioJapan 2025, including a visit to Astellas Pharma, a prominent Japanese multinational pharmaceutical company. This visit will include a tour of Astellas’ innovative SakuLab facility, where discussions will focus on potential collaborations in cell therapy and bioprocessing.

A significant highlight of the event will be the signing of a memorandum of understanding (MOU) between Creative Life Science and Myoridge, a Japanese firm. This agreement aims to leverage their combined expertise in cell culture and production to explore new possibilities in regenerative medicine.

The complete list of Taiwan’s biotech delegation reflects a diverse representation of the industry, showcasing the nation’s commitment to fostering a robust biotech ecosystem. For further details, visit the official website at https://ccd.nat.gov.tw/biopharm.

Media inquiries can be directed to Janet Chung at [email protected].